Vedolizumab and Anti-TNFα
Real-World Outcomes in
Biologic-Naïve IBD Patients:
Results from the EVOLVE Study
An important study looking at which biologic (vedolizumab or anti-TNF agents) is more effective and safer as a patient's first biological. Read more